Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease

Cardiology in the Young

Volumn 19, Issue 5, 2009, Pages 431-435

  Lopes, Antonio Augusto ^a   Oleary, Patrick W ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b MAYO CLINIC   (United States)

Author keywords

Congenital heart disease; Pulmonary hypertension; Pulmonary vascular resistance; Pulmonary vasoreactivity

Indexed keywords

FENTANYL; KETAMINE; MIDAZOLAM; NITRIC OXIDE; OXYGEN; PROPOFOL; REMIFENTANIL;

CHILD CARE; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; CONGENITAL HEART DISEASE; DISEASE ASSOCIATION; DRUG INDICATION; FONTAN PROCEDURE; HEALTH SURVEY; HEART CATHETERIZATION; HEART RIGHT LEFT SHUNT; HEMODYNAMIC MONITORING; HEMODYNAMIC PARAMETERS; HUMAN; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; PATIENT SELECTION; PREMEDICATION; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; PULMONARY HYPERTENSION; REVIEW; ANESTHESIA; ARTICLE; HEART DISEASE; HEMODYNAMICS; INFANT; PATHOPHYSIOLOGY;

ANESTHESIA; HEART CATHETERIZATION; HEART DISEASES; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; INFANT;

EID: 75549083677     PISSN: 10479511     EISSN: 14671107     Source Type: Journal    
DOI: 10.1017/S1047951109990771     Document Type: Review

References (22)

1. Berger RMF. Possibilities and impossibilities in the evaluation of pulmonary vascular disease in congenital heart defects. Eur Heart J 2000; 21: 17-27.
2. Wilkinson JL. Congenital heart disease: haemodynamic calculations in the catheter laboratory. Heart 2001; 85: 113-120.
3. Laird TH, Stayer SA, Rivenes SM, et al. Pulmonary-to-systemic blood flow ratio effects of Sevoflurane, Isoflurane, Halothane, and Fentanyl/Midazolam with 100% oxygen in children with congenital heart disease. Anaesth Analg 2002; 95: 1200-1206.
4. Williams GD, Jones TK, Hanson KA, Morray JP. The haemodynamic effects of Propofol in children with congenital heart disease. Anaesth Analg 1999; 89: 1411-1416.
5. ÖklÜE, Bulutcu FS, Yalçin Y, Ozbek U, Cakali E, Bayindir O. Which anaesthetic agent alters the haemodynamic status during paediatric catheterization? Comparison of Propofol versus Ketamine. J Cardiothorac Vasc Anaesth 2003; 17: 686-690.
6. Berman W Jr, Fripp RR, Rubler M, Alderete L. Haemodynamic effects of Ketamine in children undergoing cardiac catheterization. Pediatr Cardiol 1990; 11: 72-76.
7. Jobeir A, Galal MO, Bulbul ZR, Solymar L, Darwish A, Schmaltz AA. Use of low-dose Ketamine and/or Midazolam for paediatric cardiac catheterization: is an anaesthesiologist needed? Pediatr Cardiol 2003; 24: 236-243.
8. Kogan A, Efrat R, Katz J, Vidne BA. Propofol-Ketamine mixture for anaesthesia in paediatric patients undergoing cardiac catheterization. J Cardiothorac Vasc Anaesth 2003; 17: 691-693.
9. LaFarge CG, Miettinen OS. The estimation of oxygen consumption. Cardiovasc Res 1970; 4: 23-30.
10. Lindahl SGE. Oxygen consumption and carbon dioxide elimination in infants and children during anaesthesia and surgery. Br J Anaesth 1989; 62: 70-76.
11. Bergstra A, van Dijk RB, Hillege HL, Lie KI, Mook GA. Assumed oxygen consumption based on calculation from dye dilution cardiac output: an improved formula. Eur Heart J 1995; 16: 698-703.
12. Lundell BPW, Casas ML, Wallgren CG. Oxygen consumption in infants and children during heart catheterization. Pediatr Cardiol 1996; 17: 207-213.
13. Shanahan CL, Wilson NJ, Gentles TL, Skinner JR. The influence of measured versus assumed uptake of oxygen in assessing pulmonary vascular resistance in patients with a bidirectional Glenn anastomosis. Cardiol Young 2003; 13: 137-142.
14. Berner M, Beghetti M, Spahr-Schopfer I, Oberhansli I, Friedli B. Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease. Am J Cardiol 1996; 77: 532-535.
15. Atz AM, Adatia I, Lock JE,Wessel DL. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol 1999; 33: 813-819.
16. Balzer DT, Kort HW, Day RW, et al. Inhaled nitric oxide as a preoperative test (INOP test I). Circulation 2002; 106 (Suppl I): I76-I81.
17. Khambdkone S, Li J, de Leval MR, Cullen S, Deanfield JE, Redington AN. Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation. Circulation 2003; 107: 3204-3208.
18. Mair DD, Hagler DJ, Puga FJ, Schaff HV, Danielson GK. Fontan operation in 176 patients with tricuspid atresia: results and a proposed new index for patient selection. Circulation 1990; 82 (Suppl): IV169.
19. Roberts JD Jr, Lang P, Bigatello LM, Vlahakes GJ, Zapol WM. Inhaled nitric oxide in congenital heart disease. Circulation 1993; 87: 447-453.
20. Rimensberger PC, Spahr-Schopfer I, Berner M, et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease. Vasodilator capacity and cellular mechanisms. Circulation 2001; 103: 544-548.
21. Cannon BC, Feltes TF, Fraley JK, Grifka RG, Riddle EM, Kovalchin JP. Nitric oxide in the evaluation of congenital heart disease with pulmonary hypertension: factors related to nitric oxide response. Pediatr Cardiol 2005; 26: 565-569.
22. Turanlahti MI, Laitinen PO, Sarna SJ, Pesonen E. Nitric oxide, oxygen, and prostacyclin in children with pulmonary hypertension. Heart 1998; 79: 169-174.